Back to top
more

Arcus Biosciences (RCUS)

(Delayed Data from NYSE)

$15.55 USD

15.55
505,353

+0.82 (5.57%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $15.56 +0.01 (0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Think Arcus Biosciences, Inc. (RCUS) Could Surge 151.61%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 151.6% in Arcus Biosciences, Inc. (RCUS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.

Exelixis (EXEL) Q4 Earnings Beat on Lower R&D Spend, Sales Miss

by Zacks Equity Research

Exelixis (EXEL) surpasses earnings estimates in the fourth quarter on lower R&D expenses. Sales, however, miss estimates.

Exelixis (EXEL) Outperforms on Cabometyx and Pipeline Progress

by Zacks Equity Research

Exelixis' (EXEL) lead drug, Cabometyx, maintains momentum on consistent demand. Efforts to develop additional drugs to expand its portfolio are poised to reap rewards.

Gilead (GILD), Compugen Collaborate for Immunotherapy Program

by Zacks Equity Research

Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.

Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data

by Zacks Equity Research

Updates from Exelixis (EXEL) and Pharvaris (PHVS) are in the spotlight this week.

Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study

by Zacks Equity Research

Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.

Arcus Biosciences, Inc. (RCUS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Adaptive Biotechnologies (ADPT): Can Its 9.5% Jump Turn into More Strength?

by Zacks Equity Research

Adaptive Biotechnologies (ADPT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Biotech Stocks Rally After Roche's (RHHBY) Accidental Data Leak

by Zacks Equity Research

Shares of several companies developing anti-TIGIT therapies rise after Roche (RHHBY) accidentally leaks encouraging late-stage study data.

Roche (RHHBY) Up on Upbeat Data From Combo Drug Cancer Study

by Zacks Equity Research

Roche's (RHHBY) stock jumps 4.3% on Wednesday after the company inadvertently publishes encouraging second interim analysis data from its combination drug study to treat cancer.

Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -4% and 19.13%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -11.96% and 62%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 10.17% and 38.89%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 10% and 3.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study

by Zacks Equity Research

Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study.

Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases

by Zacks Equity Research

Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases.

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

by Zacks Equity Research

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

TEVA Q1 Earnings Miss Estimates, Sales Beat, Stock Declines

by Zacks Equity Research

TEVA reports mixed Q1 results, missing earnings estimates but beating the same for revenues. Stock falls.

Amicus (FOLD) Q1 Earnings Miss, Galafold Sales Grow

by Zacks Equity Research

Amicus (FOLD) incurs wider-than-expected loss in the first quarter. Revenues, however, beat estimates. The company reiterates its 2023 guidance.

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -2.83% and 4.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Intra-Cellular (ITCI) Q1 Earnings Top, Caplyta Volume Rises

by Zacks Equity Research

Intra-Cellular (ITCI) first-quarter earnings and revenues beat estimates. The company reiterates its previously issued guidance for 2023.

Puma Biotech (PBYI) Q1 Earnings Beat, Nerlynx Sales Rise Y/Y

by Zacks Equity Research

Puma Biotechnology (PBYI) earnings and sales beat estimates in Q1. Stock rises in after-hours.

Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth

by Zacks Equity Research

Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.

Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.